Kadant Inc. — Form 10-Q Summary
Period: Quarter and six months ended July 2, 2022; comparative periods ended July 3, 2021. The filing is for 2022 Q2, despite the request metadata specifying 2021 Q2. Amounts below are in U.S. dollars.
Business context and results
Kadant supplies engineered technologies and systems for industrial processing, through Flow Control, Industrial Processing, and Material Handling segments. The company reported strong demand, but cited labor and supply constraints, input and freight inflation, foreign-exchange headwinds, and signs of moderating capital demand.
| Metric | Q2 2022 | Q2 2021 | First half 2022 | First half 2021 |
|---|---|---|---|---|
| Revenue | $221.6m | $195.8m | $448.1m | $368.3m |
| Operating income | $37.5m | $33.0m | $93.4m | $56.4m |
| Net income attributable to Kadant | $26.2m | $22.9m | $67.4m | $39.4m |
| Diluted EPS | $2.24 | $1.96 | $5.77 | $3.39 |
| Consolidated gross margin | 43.3% | 43.6% | 43.3% | 43.7% |
| Adjusted EBITDA margin (non-GAAP) | 20.7% | 21.1% | 20.5% | 20.0% |
Q2 revenue rose 13% year over year, including 10% from acquisitions; organic revenue increased 8%, while currency translation reduced growth by about 5%. First-half revenue increased 22%; organic revenue grew 14%, acquisitions contributed 11%, and currency translation reduced growth by 3%. Q2 segment revenue was $85.2m in Flow Control, $84.4m in Industrial Processing, and $52.0m in Material Handling.
First-half operating income included a $20.2m gain on the sale of a Chinese facility, partly offset by a $0.2m impairment charge and other identified items. The gain materially elevated reported first-half earnings: adjusted operating income, excluding specified gains and other items, was $74.6m versus GAAP operating income of $93.4m. First-half net income also benefited from the gain. The facility sale generated a $15.1m after-tax gain.
Cash flow, debt and liquidity
- First-half operating cash flow was $42.6m, down from $63.5m. Inventory and receivables absorbed $39.2m, including $26.8m for inventory supporting orders expected to ship in late 2022 and early 2023.
- Capital expenditures were $9.8m; reported free cash flow, a non-GAAP measure, was $32.8m versus $59.2m a year earlier.
- Cash and cash equivalents were $76.5m at July 2, 2022, compared with $91.2m at January 1, 2022. Cash, cash equivalents, and restricted cash totaled $78.0m.
- Total debt obligations were $228.3m, including $210.5m outstanding on the revolving facility. The company reported $189.0m of available capacity, a 1.05 leverage ratio, and compliance with debt covenants. The facility matures December 14, 2023.
- Working capital was $181.0m, versus $162.4m at fiscal year-end. The company said existing cash, operating cash generation, borrowing capacity, and debt-market access should cover requirements for the next 12 months and foreseeable future.
Outlook, management commentary and risks
- Bookings were $265.9m in Q2, near the Q1 record of $266.1m; backlog reached a record $379.2m. Management expected bookings to be lower in the second half than in the first half as demand moderates, inflation-control measures affect end markets, and customers reassess capital spending.
- Management described business fundamentals as positive, supported by backlog and demand, while warning that labor availability, supply constraints, inflation, longer lead times, freight costs, and the strong U.S. dollar would continue to challenge operations. The company expected unfavorable currency translation to persist through the rest of 2022.
- Planned remaining-2022 capital expenditures were approximately $21m–$23m, including spending on a new Chinese manufacturing facility. The overall facility project was estimated at about $20m over two years, partly offset by proceeds from the sale of the existing site.
- The board authorized up to $50m in share repurchases through May 19, 2023; none had been made under that authorization as of the filing. First-half dividends paid were $5.9m; a $0.26-per-share dividend was declared for payment in August 2022.
- Key disclosed risks include COVID-19 and China’s zero-COVID policy, geopolitical tensions and sanctions, tariffs and trade restrictions, foreign-exchange movements, supply-chain disruption, inflation, and potential customer delays or cancellations of capital projects. Litigation and customary recourse exposure on certain transferred Chinese bank drafts were also disclosed; the filing provides no clear quantified expected loss for these matters.
Important facts for investors to verify
- Assess how much reported earnings growth reflects recurring operations versus the $20.2m facility-sale gain, and review the company’s non-GAAP adjustments.
- Track working-capital investment, especially inventory and receivables, and whether backlog converts to revenue and cash as expected.
- Monitor second-half bookings, customer capital-spending decisions, supply and labor constraints, and the effects of foreign currency and tariffs on margins.
- Review debt refinancing plans ahead of the December 2023 revolving-facility maturity, covenant headroom, and the use of borrowing capacity.
- Confirm timing and remaining proceeds from the Chinese facility sale, costs and schedule for the replacement facility, and any material developments in the disclosed risks or contingencies.